ID   LA-N-1
AC   CVCL_1827
SY   LAN-1; LAN1; Lan1
DR   BTO; BTO:0003542
DR   CLO; CLO_0007240
DR   CLO; CLO_0051542
DR   EFO; EFO_0005391
DR   ArrayExpress; E-MTAB-783
DR   BioSample; SAMN03472327
DR   BioSample; SAMN03473468
DR   cancercelllines; CVCL_1827
DR   Cosmic; 801740
DR   Cosmic; 920240
DR   Cosmic; 947710
DR   Cosmic; 1019927
DR   Cosmic; 1037343
DR   Cosmic; 1099140
DR   Cosmic; 1109118
DR   Cosmic; 1153781
DR   Cosmic; 1153809
DR   Cosmic; 1161991
DR   Cosmic; 1167411
DR   Cosmic; 1526627
DR   Cosmic; 2131578
DR   Cosmic; 2239461
DR   Cosmic; 2301574
DR   Cosmic; 2393635
DR   Cosmic; 2485946
DR   DSMZ; ACC-655
DR   DSMZCellDive; ACC-655
DR   ECACC; 06041201
DR   GEO; GSM313802
DR   GEO; GSM333797
DR   GEO; GSM563355
DR   GEO; GSM692872
DR   GEO; GSM1366408
DR   IARC_TP53; 21458
DR   ICLC; HTL98005
DR   Progenetix; CVCL_1827
DR   RCB; RCB0483
DR   TOKU-E; 4118
DR   Wikidata; Q54901875
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=856461;
RX   PubMed=2535691;
RX   PubMed=7037175;
RX   PubMed=7838528;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18082704;
RX   PubMed=18165268;
RX   PubMed=18724359;
RX   PubMed=18923523;
RX   PubMed=18923524;
RX   PubMed=20164919;
RX   PubMed=20655465;
RX   PubMed=22213050;
CC   Doubling time: ~100 hours (DSMZ=ACC-655); ~2 days (ECACC=06041201).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18724359; PubMed=18923523).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ICLC; HTL98005; true.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): COG; DSMZ; ECACC; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 14
ST   D19S433: 13
ST   D21S11: 29,36
ST   D2S1338: 16,21
ST   D3S1358: 16,16.2
ST   D5S818: 12
ST   D7S820: 10 (COG)
ST   D7S820: 10,11 (DSMZ; ECACC; RCB)
ST   D8S1179: 13,14
ST   FGA: 19,24
ST   Penta D: 9,13
ST   Penta E: 11,12
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 16,19
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=856461;
RA   Seeger R.C., Rayner S.A., Banerjee A., Chung H., Laug W.E.,
RA   Neustein H.B., Benedict W.F.;
RT   "Morphology, growth, chromosomal pattern and fibrinolytic activity of
RT   two new human neuroblastoma cell lines.";
RL   Cancer Res. 37:1364-1371(1977).
//
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
//
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
//
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18082704; DOI=10.1016/j.jpedsurg.2007.08.026;
RA   Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M.,
RA   Hayashi Y.;
RT   "Identification of side population cells (stem-like cell population)
RT   in pediatric solid tumor cell lines.";
RL   J. Pediatr. Surg. 42:2040-2045(2007).
//
RX   PubMed=18165268; DOI=10.2353/ajpath.2008.061263;
RA   Stock C., Bozsaky E., Watzinger F., Poetschger U., Orel L., Lion T.,
RA   Kowalska A., Ambros P.F.;
RT   "Genes proximal and distal to MYCN are highly expressed in human
RT   neuroblastoma as visualized by comparative expressed sequence
RT   hybridization.";
RL   Am. J. Pathol. 172:203-214(2008).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=18923523; DOI=10.1038/nature07398;
RA   Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A.,
RA   de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G.,
RA   Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S.,
RA   Amiel J., Delattre O.;
RT   "Somatic and germline activating mutations of the ALK kinase receptor
RT   in neuroblastoma.";
RL   Nature 455:967-970(2008).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//